GeNeuro Successfully Completes Phase 2a Clinical Study With Novel Approach to Treat Multiple Sclerosis
GENEVA & LYON & ARCHAMPS, France--(BUSINESS WIRE)--GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study. GNbaC1 is a first-in-class monoclonal antibody targeting a toxic protein of endogenous retroviral origin that has been identified as a potential key factor in the onset and development of multiple sclerosis. Enrollment of patients into a multinational Phase 2b study is expected to begin during the first half 2014.
Help employers find you! Check out all the jobs and post your resume.